Qisda

Qisda has rapidly expanded its healthcare business to become a major revenue driver. The company operates two large general hospitals in China and Taiwan, manufactures a wide range of medical equipment—including hemodialysis machines and imaging systems—and has invested in precision medicine through partnerships such as with TCI Gene Inc. Its healthcare segment generated over US$600 million in revenue in 2023 and was projected to approach US$1 billion by the end of 2024. The group’s medical offerings span hospital services, medical consumables/devices, digital dentistry solutions, dialysis products/services, hearing aids/services, genetic testing platforms for precision medicine applications, and more. No clinical trial results or drug development pipeline typical of biotech/pharma companies were found; instead the focus remains on commercialized devices/services.[8][10]